menu toggle

Cencora's Brian Biehn and Corey Ford recommend adaptations for biosimilar regulatory frameworks

By AmerisourceBergen

Brian Biehn and Corey Ford from Cencora suggest improvements to current regulatory frameworks to better promote biosimilars for US patients and ensure market sustainability.

On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will change the space going forward.

Brian Biehn, senior director of biosimilar commercialization, and Corey Ford, vice president of reimbursement and policy insights at Cencora (formerly AmerisourceBergen) describe different avenues for regulatory agencies to improve biosimilar promotion and create a sustainable biosimilar industry.